Covid-19: Evusheld protects the most vulnerable patients, analysis shows

The antibody drug Evusheld is effective for protecting clinically extremely vulnerable people from covid-19, including its omicron variants, a preprint study has reported.1The prophylactic treatment, manufactured by AstraZeneca, is a combination of two long acting antibodies (tixagevimab and cilgavimab). It is given as two separate, sequential intramuscular injections in the same session and can be administered in the community.A research team, led by the University of Birmingham alongside academics from King’s College London and the UK Health Security Agency, carried out a systematic review and meta-analysis to examine its effectiveness in immunocompromised patients.The paper, published as a preprint ahead of peer review, examined the outcomes among 24 773 immunocompromised participants across 17 international studies, 10 775 of whom received Evusheld.Overall, it reported that the treatment was 86% (95% confidence interval 6.2% to 99.7%; P=0.04) effective for preventing covid specific death, 88% (47.1% to 98.7%; P<0.001) effective in preventing intensive care... Read Original Article: Covid-19: Evusheld protects the most vulnerable patients, analysis shows »